Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2026)
Inovio Pharmaceuticals (INO) posted Operating Leases of $5.8 million for Q1 2026, down 11.6% sequentially from $6.5 million in Q4 2025, and down 33.45% YoY from $8.7 million in Q1 2025.
Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Operating Leases fell 33.45% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 33.45% YoY) and the FY2025 annual result came in at $6.5 million, down 30.13% from the prior year.
- Operating Leases fell to $5.8 million in Q1 2026 per INO's latest filing, from $6.5 million in the prior quarter.
- Over five years, Operating Leases peaked at $16.1 million in Q3 2022 and troughed at $5.8 million in Q1 2026.
- A 5-year average of $11.0 million and a median of $11.2 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases increased 11.17% in 2024, then tumbled 41.49% in 2025.
- Over 5 years, Operating Leases stood at $12.7 million in 2022, then decreased by 12.83% to $11.0 million in 2023, then decreased by 15.09% to $9.4 million in 2024, then plunged by 30.13% to $6.5 million in 2025, then dropped by 11.6% to $5.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $5.8 million, $6.5 million, and $7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - |
| 10 | Inovio Pharmaceuticals | 97.13 Mn | 97.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.00 Mn |
| Mar 31, 2026 | 5.79 Mn |
| Dec 31, 2025 | 6.55 Mn |
| Sep 30, 2025 | 7.28 Mn |
| Jun 30, 2025 | 10.66 Mn |
| Mar 31, 2025 | 8.70 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 12.45 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 11.27 Mn |
| Dec 31, 2023 | 11.03 Mn |
| Sep 30, 2023 | 11.19 Mn |
| Jun 30, 2023 | 11.70 Mn |
| Mar 31, 2023 | 12.19 Mn |
| Dec 31, 2022 | 12.66 Mn |
| Sep 30, 2022 | 16.13 Mn |
| Jun 30, 2022 | 14.05 Mn |
| Mar 31, 2022 | 14.77 Mn |
| Dec 31, 2021 | 15.46 Mn |
| Sep 30, 2021 | 18.67 Mn |